CYTH Stock Overview
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Cyclo Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.40 |
52 Week High | US$2.57 |
52 Week Low | US$0.67 |
Beta | -0.14 |
1 Month Change | -17.65% |
3 Month Change | -9.09% |
1 Year Change | 57.29% |
3 Year Change | -82.95% |
5 Year Change | -97.88% |
Change since IPO | -99.30% |
Recent News & Updates
Recent updates
Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M
Aug 16Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation
Jul 12We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate
Jan 20Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease
Nov 16Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?
Sep 28Cyclo therapeutics to join Russell 2000 Index
Jun 14We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate
Jun 12Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo
Apr 27Cyclo Therapeutics' lead candidate shows durable benefit in Niemann-Pick Disease
Jan 05How Much Is Cyclo Therapeutics, Inc. (NASDAQ:CYTH) CEO Getting Paid?
Dec 12Shareholder Returns
CYTH | US Biotechs | US Market | |
---|---|---|---|
7D | -2.1% | 0.9% | 0.4% |
1Y | 57.3% | 10.3% | 28.8% |
Return vs Industry: CYTH exceeded the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: CYTH exceeded the US Market which returned 29.5% over the past year.
Price Volatility
CYTH volatility | |
---|---|
CYTH Average Weekly Movement | 12.1% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CYTH's share price has been volatile over the past 3 months.
Volatility Over Time: CYTH's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 8 | N. Fine | https://cyclotherapeutics.com |
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company’s lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer’s disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
Cyclo Therapeutics, Inc. Fundamentals Summary
CYTH fundamental statistics | |
---|---|
Market cap | US$40.20m |
Earnings (TTM) | -US$20.06m |
Revenue (TTM) | US$1.08m |
37.3x
P/S Ratio-2.0x
P/E RatioIs CYTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CYTH income statement (TTM) | |
---|---|
Revenue | US$1.08m |
Cost of Revenue | US$98.46k |
Gross Profit | US$977.95k |
Other Expenses | US$21.04m |
Earnings | -US$20.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.70 |
Gross Margin | 90.85% |
Net Profit Margin | -1,863.36% |
Debt/Equity Ratio | 0% |
How did CYTH perform over the long term?
See historical performance and comparison